| Record ID | marc_records_scriblio_net/part15.dat:223599797:1268 |
| Source | Scriblio |
| Download Link | /show-records/marc_records_scriblio_net/part15.dat:223599797:1268?format=raw |
LEADER: 01268cam 2200325 a 4500
001 82042744 //r913
003 DLC
005 19910516091037.0
008 830422s1983 nyua b 00100 eng
010 $a 82042744 //r913
020 $a0890048886
040 $aDLC$cDLC$dDLC$dOCoLC
050 10 $aRC271.M57$bN48 1983
060 $aW1 MO559U v. 12$aQZ 267 N5312 1981
082 00 $a616.99/4061$219
245 00 $aNew anticancer drugs :$bmitoxantrone and bisantrene /$ceditors, Marcel Rozencweig, Daniel D. Von Hoff, Maurice J. Staquet.
260 0 $aNew York :$bRaven Press,$cc1983.
300 $axv, 194 p. :$bill. ;$c25 cm.
440 0 $aMonograph series of the European Organization for Research on Treatment of Cancer ;$vv. 12
504 $aIncludes bibliographies and indexes.
650 0 $aMitoxantrone hydrochloride$xTesting.
650 0 $aBisantrene hydrochloride$xTesting.
650 0 $aCancer$xChemotherapy$xEvaluation.
650 2 $aAnthracenes$xTherapeutic use$xCongresses.
650 2 $aAnthraquinones$xTherapeutic use$xCongresses.
650 2 $aAntineoplastic agents$xTherapeutic use$xCongresses.
650 2 $aNeoplasms$xDrug therapy$xCongresses.
700 10 $aRozencweig, Marcel.
700 10 $aVon Hoff, Daniel D.
700 10 $aStaquet, Maurice J.